As per the research report, the size of the North America Biopharmaceutical contract manufacturing market is valued at USD 1.72 billion in 2023. It is expected to rise at a CAGR of 10% and expand to USD 2.76 billion by 2028.
A contract manufacturing organization is a company that provides comprehensive services to other biopharmaceutical firms on a contract basis, ranging from drug development to medicine production. It enables large biopharmaceutical companies to outsource certain aspects of their operations, concentrating on medicine development and marketing. The biotechnology sector continues to outsource to contract manufacturing businesses to meet its fill-and-finish needs and reduce risk.
Also, due to a lack of in-house capacity, several small biotechnology organizations outsource their fill and finish manufacturing needs, which helps organizations retain capital expenditures and lowers the risk involved in the business. Furthermore, these firms' outsourcing strategy is complicated and changes based on the product life cycle, product phase, volume, and profitability.
Even with the increase in the demand for outsourcing, notably in cell culture technologies and novel modalities, More than 235 businesses now provide contract manufacturing services for biopharmaceuticals with a wide range of handling biologics. Proteins/peptides, antibodies, and vaccines are among the most common services offered by contract manufacturing organizations. Furthermore, mammalian cell-based production is more common than microbial expression methods. A contract manufacturing organization is a firm that provides complete services from drug research to medication manufacture to other biopharmaceutical companies on a contract basis.
However, the prominent drivers driving the antibodies segment are the increase in the investments of the technological improvements in monoclonal antibody treatment and increased research & development efforts. As monoclonal antibody treatment is a kind of immunotherapy in which antibodies are attached to specific cells or proteins, causing the patient's immune system to destroy them. These medicinal substances are used to treat various types of malignancy. The most common type of biologic is monoclonal antibodies, and it has been approved for nearly all types of medicines.
However, an increase in the high costs of transportation costs with the rise in the competition in the market is likely to affect market growth due to strict rules and regulations for introducing the new product.
This research report on the North America Biopharmaceutical Contract Manufacturing Market has been segmented and sub-segmented into the following categories:
By Product Type:
By Therapeutic Area:
By Application:
By Country:
The North American market is geographically the largest and dominates the global North America Biopharmaceutical Contract Manufacturing Market and is estimated to account for predominant growth during the forecast period. Increase in the biopharmaceuticals contract manufacturing markets, the rise in the outsourcing volume by bio- pharmaceuticals industries, and availability of advanced technology in the region.
Moreover, Mergers, acquisitions, and joint ventures are typical industry strategies because they enable contract manufacturing organizations to provide integrated bioprocessing services, making them a more dependable alternative for a quick product launch for commercial usage. Furthermore, the growing emphasis on superior biopharmaceutical products, biosimilar, and biopharmaceutical-based research and development activities accounted for a large percentage of total research and development activities in various sectors, fueling the overall regional market growth to a large extent.
The U.S Biopharmaceutical Contract Manufacturing Market dominates the market by big pharma companies owing to the increase in the vast number of biopharmaceutical firms with substantial production capabilities and the high consumption of biologics in this area. Also, with the rise in the investment and initiatives in research and development with the increase in the competition in the market for maintaining the position.
KEY MARKET PLAYERS:
Companies playing a dominant role in the North America Biopharmaceutical contract manufacturing market profiled in this report are Lonza Group AG, Baxter Biopharma Solutions, Samsung Biologics Co., Ltd., Fujifilm Diosynth Biotechnologies, Boehringer Ingelheim GmbH, Patheon N.V., Rentschler Biotechnologie GmbH, Biomeva GmbH, Probiogen AG, Cytovance Biologics, Inc., KBI Biopharma, Inc., WuXi Biologics, Abzena Plc, Vetter Pharma International GmbH, Sandoz International GmbH, Catalent, Inc., AbbVie Contract Manufacturing (An AbbVie Company), Ajinomoto Althea Inc.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1400
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region